1. Six months after Pfizer announced its plans to acquire Biohaven Pharmaceuticals, the deal finalized Oct. 3 for $11.6 billion. One of Biohaven’s biggest assets is its portfolio of migraine brand-name drugs, including Nurtec and Vydura.
2. The pharmaceutical company’s late-stage clinical trial of talazoparib and enzalutamide delivered “topline results” among men with metastatic castration-resistant prostate cancer. Together, the treatments improved radiographic progression-free survival rates, according to an Oct. 4 news release. Pfizer said it is still analyzing secondary endpoints.
